$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000168316824003688 Filed on May 20, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$9.303M	$7.541M	$4.894M
YoY Change	67.3%	54.09%	3890.26%
Cost Of Revenue	$6.947M	$5.187M	$3.066M
YoY Change	92.53%	69.17%	5022.69%
Gross Profit	$2.356M	$2.354M	$1.828M
YoY Change	20.66%	28.78%	2811.02%
Gross Profit Margin	25.33%	31.22%	37.35%
Selling, General & Admin	$3.881M	$3.903M	$3.785M
YoY Change	26.18%	3.12%	310.79%
% of Gross Profit	164.7%	165.78%	207.04%
Research & Development	$436.2K	$222.0K	$432.9K
YoY Change	18.36%	-48.71%	19.71%
% of Gross Profit	18.51%	9.43%	23.68%
Depreciation & Amortization	$50.87K	$42.60K	$34.71K
YoY Change	45.86%	22.73%	1016.08%
% of Gross Profit	2.16%	1.81%	1.9%
Operating Expenses	$4.317M	$4.125M	$4.218M
YoY Change	25.35%	-2.2%	227.95%
Operating Profit	-$1.268M	-$1.351M	-$1.829M
YoY Change	28.16%	-26.16%	49.5%
Interest Expense	$430.3K	$49.18K	$41.08K
YoY Change	1459.21%	19.73%	-419.15%
% of Operating Profit
Other Income/Expense, Net	$430.3K	$89.14K	$172.8K
YoY Change	145.61%	-48.42%	-1442.82%
Pretax Income	-$838.0K	-$1.261M	-$1.656M
YoY Change	2.89%	-23.83%	33.97%
Income Tax	-$343.7K	$22.35K	$46.27K
% Of Pretax Income
Net Earnings	-$494.3K	-$1.284M	-$1.702M
YoY Change	-45.21%	-24.59%	37.71%
Net Earnings / Revenue	-5.31%	-17.02%	-34.79%
Basic Earnings Per Share	-$9.94	-$2.00	-$7.73
Diluted Earnings Per Share	-$9.94	-$2.00	-$0.08
COMMON SHARES
Basic Shares Outstanding	18.95M shares	99.45M shares	22.59M shares
Diluted Shares Outstanding	49.73K shares	641.3K shares	22.04M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.51M	$17.43M	$19.29M
YoY Change	-41.67%	-9.64%	46.42%
Cash & Equivalents	$11.51M	$17.43M	$19.29M
Short-Term Investments
Other Short-Term Assets	$1.776M	$871.0K	$152.3K
YoY Change	1559.95%	472.05%	229.42%
Inventory	$8.491M	$7.698M	$3.710M
Prepaid Expenses	$1.776M	$871.4K	$152.3K
Receivables	$3.974M	$2.828M	$1.790M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$25.75M	$28.83M	$24.95M
YoY Change	-1.34%	15.57%	86.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$541.4K	$401.6K	$368.0K
YoY Change	47.65%	9.13%	9147.04%
Goodwill
YoY Change
Intangibles	$2.447M	$2.066M	$948.2K
YoY Change	98.38%	117.84%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.552M	$3.067M	$2.044M
YoY Change	53.7%	50.04%	51396.25%
TOTAL ASSETS
Total Short-Term Assets	$25.75M	$28.83M	$24.95M
Total Long-Term Assets	$3.552M	$3.067M	$2.044M
Total Assets	$29.30M	$31.90M	$26.99M
YoY Change	3.14%	18.18%	101.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.930M	$3.615M	$2.736M
YoY Change	180.15%	32.13%	2773.21%
Accrued Expenses	$114.5K	$115.0K	$121.3K
YoY Change	-6.3%	-5.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.299M	$6.533M	$6.906M
YoY Change	13.71%	-5.39%	7151.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$462.9K	$497.0K	$613.1K
YoY Change	-22.44%	-18.94%
Total Long-Term Liabilities	$511.6K	$545.7K	$656.2K
YoY Change	-20.04%	-16.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.299M	$6.533M	$6.906M
Total Long-Term Liabilities	$511.6K	$545.7K	$656.2K
Total Liabilities	$5.811M	$7.079M	$7.562M
YoY Change	9.64%	-6.38%	7840.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.68M	-$65.19M	-$61.10M
YoY Change	5.93%	6.69%
Common Stock	$1.171K	$995.00	$22.14K
YoY Change	-95.45%	-95.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.49M	$24.82M	$19.43M
YoY Change
Total Liabilities & Shareholders Equity	$29.30M	$31.90M	$26.99M
YoY Change	3.14%	18.18%	101.29%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$494.3K	-$1.284M	-$1.702M
YoY Change	-45.21%	-24.59%	37.71%
Depreciation, Depletion And Amortization	$50.87K	$42.60K	$34.71K
YoY Change	45.86%	22.73%	1016.08%
Cash From Operating Activities	-$4.578M	-$3.185M	-$1.850M
YoY Change	21.17%	72.16%	41.86%
INVESTING ACTIVITIES
Capital Expenditures	$572.2K	$699.8K	$178.4K
YoY Change	94.48%	292.26%
Acquisitions
YoY Change
Other Investing Activities	$29.98K	$31.10K	$32.09K
YoY Change	-13.75%	-3.09%
Cash From Investing Activities	-$542.2K	-$668.7K	-$146.3K
YoY Change	108.97%	357.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-28.53K	$5.398M	-$538.3K
YoY Change	-100.7%	-1102.82%	-104.33%
NET CHANGE
Cash From Operating Activities	-4.578M	-$3.185M	-$1.850M
Cash From Investing Activities	-542.2K	-$668.7K	-$146.3K
Cash From Financing Activities	-28.53K	$5.398M	-$538.3K
Net Change In Cash	-5.149M	$1.544M	-$2.535M
YoY Change	-25276.09%	-160.92%	-122.77%
FREE CASH FLOW
Cash From Operating Activities	-$4.578M	-$3.185M	-$1.850M
Capital Expenditures	$572.2K	$699.8K	$178.4K
Free Cash Flow	-$5.150M	-$3.885M	-$2.029M
YoY Change	26.46%	91.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401642	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	365868	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2065603	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1444259	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	600248	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646779	usd
CY2024Q1	us-gaap	Assets Assets	31898717	usd
CY2023Q4	us-gaap	Assets Assets	27346961	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3615205	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2585466	usd
CY2024Q1	SBFM	Earnout Payable EarnoutPayable	2547831	usd
CY2023Q4	SBFM	Earnout Payable EarnoutPayable	2547831	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	254971	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	299869	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	115398	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118670	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6533405	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5551836	usd
CY2024Q1	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	48729	usd
CY2023Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	48729	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	496968	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	539035	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	545697	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	587764	usd
CY2024Q1	us-gaap	Liabilities Liabilities	7079102	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6139600	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	13000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	994529	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	994529	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	280243	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	280243	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	995	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28024	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89842680	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84387890	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	152400	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	696105	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65189459	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63905658	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	24819615	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21207361	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31898717	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27346961	usd
CY2024Q1	us-gaap	Revenues Revenues	7541046	usd
CY2023Q1	us-gaap	Revenues Revenues	4894053	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	5186709	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	3065931	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	2354337	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1828122	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	352006	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	169750	usd
CY2024Q1	SBFM	Consulting Expense ConsultingExpense	47401	usd
CY2023Q1	SBFM	Consulting Expense ConsultingExpense	131615	usd
CY2024Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2023Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2024Q1	us-gaap	Legal Fees LegalFees	221998	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	107449	usd
CY2024Q1	us-gaap	Marketing Expense MarketingExpense	198046	usd
CY2023Q1	us-gaap	Marketing Expense MarketingExpense	127913	usd
CY2024Q1	SBFM	Office Expense OfficeExpense	911211	usd
CY2023Q1	SBFM	Office Expense OfficeExpense	482458	usd
CY2024Q1	SBFM	Patent Fees PatentFees	0	usd
CY2023Q1	SBFM	Patent Fees PatentFees	6308	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222033	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	432925	usd
CY2024Q1	us-gaap	Salaries And Wages SalariesAndWages	1533712	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	2000257	usd
CY2024Q1	SBFM	Taxes Taxes	75901	usd
CY2023Q1	SBFM	Taxes Taxes	63718	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42618	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34710	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3704926	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3657103	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1350589	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1828981	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5767	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	15	usd
CY2024Q1	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	144089	usd
CY2023Q1	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	213881	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	49181	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1656160	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22353	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172821	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1261448	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	41075	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	89141	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	46270	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1283801	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1702430	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-543705	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	11160	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1827506	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1691270	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.00
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.00
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.73
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.73
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	641310	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	641310	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	220363	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	220363	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1283801	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1702430	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42618	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34710	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	12000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	536261	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-135891	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2100281	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	417318	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	568981	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-129849	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1293372	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-73661	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-43824	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	42853	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3185159	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1850106	usd
CY2024Q1	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	31066	usd
CY2023Q1	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	32934	usd
CY2024Q1	SBFM	Cash From Nora Pharma Acquisition CashFromNoraPharmaAcquisition	-0	usd
CY2023Q1	SBFM	Cash From Nora Pharma Acquisition CashFromNoraPharmaAcquisition	1135	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	636865	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	178395	usd
CY2024Q1	SBFM	Payments For Proceeds From Acquire Property Plant And Equipment PaymentsForProceedsFromAcquirePropertyPlantAndEquipment	62937	usd
CY2023Q1	SBFM	Payments For Proceeds From Acquire Property Plant And Equipment PaymentsForProceedsFromAcquirePropertyPlantAndEquipment	-293	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-668736	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-146303	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8522411	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	45000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024Q1	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	3139651	usd
CY2023Q1	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	506822	usd
CY2024Q1	SBFM	Payment For Lease Liability PaymentForLeaseLiability	29611	usd
CY2023Q1	SBFM	Payment For Lease Liability PaymentForLeaseLiability	31477	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5398149	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	73998	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	73998	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	73998	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	39697	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-538299	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16292347	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1544254	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2534708	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	141312	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2489	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-543705	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17434208	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19294218	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	956012	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q1	SBFM	Stock Issued For Services StockIssuedForServices	12000	usd
CY2023Q1	SBFM	Stock Issued For Services StockIssuedForServices	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2023Q1	SBFM	Repurchase Stock RepurchaseStock	506822	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1691270	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19429478	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21207361	usd
CY2024Q1	SBFM	Preferred Stock Issued To Related Party PreferredStockIssuedToRelatedParty	12000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8522411	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	45000	usd
CY2024Q1	SBFM	Repurchase Warrants RepurchaseWarrants	-3139651	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1827506	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	24819615	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-100 reverse split of its common stock
CY2024Q1	SBFM	Gross Proceeds From Public Offering GrossProceedsFromPublicOffering	10000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8522411	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1908	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	115398	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	496968	usd
CY2024Q1	SBFM	Lessee Operating Leases Remaining Lease Term LesseeOperatingLeasesRemainingLeaseTerm	5 years 9 months
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2024Q1	SBFM	Units Description UnitsDescription	The offering consisted of 714,286 Units, consisting of (i) 264,286 Common Units, with each Common Unit consisting of one share of common stock, one-tenth of a Series A warrant to purchase one share of common stock (“Series A Warrant”) and two-tenths of a Series B warrant to purchase one share of common stock (“Series B Warrant”), and (ii) 450,000 Pre-Funded Units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock (“Pre-Funded Warrants”), one-tenth of a Series A Warrant and two-tenths of a Series B Warrant. The public offering price was $14.00 per Common Unit and $13.9 per Pre-Funded Unit. The Pre-Funded Warrants have an exercise price of $0.10 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant is $210.00 per share of common stock or pursuant to an alternative cashless exercise option. Under the alternative cashless exercise provision, which became effective following stockholder approval in March 2024, each Series A Warrant is exercisable on a cashless basis for two shares of common stock. The Series A Warrants are exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant is $238.00 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date.
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1444259	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	776856	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	679834	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	710372	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2124093	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1487228	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	58490	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	42969	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2065603	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1444259	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	714286	shares
CY2024Q1	us-gaap	Dividends Dividends	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1283801	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1702430	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	641310	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	220363	shares
CY2024Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2023Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	641310	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	220363	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.00
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.73
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	600248	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	86221	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	116020	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	109890	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	103506	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	97493	usd
CY2024Q1	SBFM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	99236	usd
CY2024Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	262486	usd
CY2023Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	820000	usd
CY2024Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2023Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2683	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2683	pure
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-003688-index-headers.html	Edgar Link	pending
0001683168-24-003688-index.html	Edgar Link	pending
0001683168-24-003688.txt	Edgar Link	pending
0001683168-24-003688-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20240331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10q-33124.htm	Edgar Link	pending
sbfm-20240331_cal.xml	Edgar Link	unprocessable
sbfm-20240331_def.xml	Edgar Link	unprocessable
sbfm-20240331_lab.xml	Edgar Link	unprocessable
sbfm-20240331_pre.xml	Edgar Link	unprocessable
sunshine_i10q-33124_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2024 Q2 Form 10-Q Financial Statement

#000168316824003688 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2024 Q2 Form 10-Q Financial Statement

#000168316824003688 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm